Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roivant's Ramaswamy Woos Celgene's Fouse To Lead Dermavant

Executive Summary

The former Celgene president has joined Roivant subsidiary Dermavant with big ambitions to turn the start up into a dermatology leader. Ramaswamy and Fouse talk about next steps for the start up.

You may also be interested in...



Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure

Axovant's stock fell 74% based on intepirdine's Phase III failure, but parent company Roivant recently raised $1.1bn, showing that investors were willing to fund more new Vants regardless of the risky study's outcome.

Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies

Roivant will use the cash to fund other "Vants" that develop drugs or make the process more efficient. Also, Zealand launches its IPO, Apellis raises a $60m Series E and BioMarin tops recent offerings.

Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation

As the CEO of Axovant, David Hung is back where he started with Medivation – working on a drug for Alzheimer's disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel